Coya Therapeutics Publishes Preclinical Data Showing Complementary Immunomodulatory Effects of COYA 303 in Neuroinflammation Model
核心洞察
Coya Therapeutics published preclinical results for COYA 303 (搜索), a combination of proprietary low-dose IL-2 and a GLP-1 receptor agonist (搜索), in the International Journal of Molecular Sciences.
In a subacute low-dose LPS mouse model, the combination produced complementary immunomodulatory effects compared with either low-dose IL-2 or GLP-1RA as monotherapy.
The GLP-1RA attenuated myeloid expansion and inflammatory transcriptional responses, while low-dose IL-2 increased regulatory T cell numbers and suppressive-function transcripts.
Coya Therapeutics, Inc. (NASDAQ: COYA) announced the publication of preclinical results for COYA 303 (搜索), an investigational combination of proprietary low-dose IL-2 (LD-IL2) and a GLP-1 receptor agonist (搜索) (GLP-1RA), in the International Journal of Molecular Sciences. The paper appeared as part of the Special Issue, "The Roles of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Health and Disease," which highlights the expanding therapeutic applications of GLP-1 receptor agonists across diverse disease settings, including their emerging immunomodulatory effects.
The study reported complementary immunomodulatory effects of the combination compared with either LD-IL2 or GLP-1RA administered as monotherapy. According to the company, GLP-1RA attenuated myeloid expansion and inflammatory transcriptional responses, whereas LD-IL2 increased regulatory T cell (Treg) numbers and transcripts associated with Treg stability and suppressive function.
Study Design and Model
COYA 303 (搜索) was evaluated in a subacute low-dose lipopolysaccharide (LPS) mouse model. The LPS model recapitulates key features relevant to neurodegenerative diseases, including increased pro-inflammatory signaling and myeloid activation leading to immune dysregulation, providing a validated setting for testing potential therapeutic interventions. The study evaluated whether simultaneously attenuating inflammatory myeloid activity and reinforcing Treg-mediated immune regulation could produce broader immunomodulatory effects than either approach alone.
Treatment with the GLP-1RA and LD-IL2 combination was initiated 24 hours after the first LPS administration, demonstrating treatment-associated effects after inflammatory induction had begun.
Peripheral and CNS Transcriptional Findings
Study animals treated with the combination showed statistically significant and clear directional effects across peripheral immune cell populations and cortical and hippocampal tissues. Peripherally, the combination produced significant reductions in pro-inflammatory myeloid interleukin 6 (IL-6) and tumor necrosis factor (TNF (搜索)) transcript expression, while increasing arginase-1 (ARG1) expression. The combination also enhanced Treg-associated IL-2 receptor alpha (IL-2Ra, also known as CD25 (搜索)), transforming growth factor beta 1 (TGF-b1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4 (搜索)) immunomodulatory transcript expression relative to monotherapies.
In the cortical and hippocampal brain regions, the combination significantly reduced pro-inflammatory IL-6 and interleukin 1 beta (IL-1b) expression while increasing CD163 and CD206 (搜索) transcript expression, markers of M2 macrophages, which are anti-inflammatory cells involved in tissue repair and remodeling. Monotherapy treatments produced limited changes across these endpoints.
In summary, the company reported that GLP-1RA and LD-IL2 combination treatment produced complementary modulation of immune cell populations and myeloid- and Treg-associated transcripts across peripheral immune cells and CNS tissues. The transcriptional response observed with the combination supports further evaluation and highlights the mechanistic potential of multi-targeted approaches as potential treatments for inflammation-driven neurodegenerative diseases.
Investigator and Company Commentary
"We are encouraged by these preclinical findings, which we believe demonstrate the therapeutic potential of immunomodulatory combinations for the treatment of serious neurodegenerative diseases characterized by sustained inflammation," said Fred Grossman, DO, FAPA, President and Chief Medical Officer of Coya. "These results continue to reinforce our belief that complex neurodegenerative diseases like amyotrophic lateral sclerosis (搜索) (ALS), frontotemporal dementia (搜索) (FTD), and Alzheimer's disease (搜索) (AD) are best addressed through a combination approach and suggest that further evaluation of this approach in chronic, disease-relevant models are needed to better understand its potential."
The study was conducted by Dr. Stanley Appel, Dr. Aaron Thome and other researchers at Houston Methodist Neurological Institute (搜索) and was funded by Coya through a sponsored research agreement with Houston Methodist Hospital Research Institute.
Product and Pipeline Context
COYA 303 (搜索) is an investigational proprietary biologic combination of low-dose IL-2 and a GLP-1 receptor agonist (搜索) designed for subcutaneous administration. In preclinical studies, COYA 303 has demonstrated a dual immunomodulatory mechanism of action targeting regulatory T cells (搜索) and pro-inflammatory myeloid cells.
Coya Therapeutics, headquartered in Houston, TX, is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (搜索) to target systemic inflammation and neuroinflammation. According to the company, dysfunctional Tregs underlie numerous conditions, including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system. Coya's investigational product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs, including Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.
Coya stated it believes the findings support further evaluation of COYA 303 (搜索) and combination approaches in addressing Alzheimer's disease (搜索) and other complex neurodegenerative indications. The company said it will continue to pursue non-dilutive avenues and potential partnerships to advance the COYA 303 program.